[Associations of serum neuromarkers with clinical features of Parkinson's disease].

Objective: To evaluate the clinical and laboratory correlation of biomarkers with anti- and pro-apoptotic activity with the severity of motor and non-motor symptoms depending on the progression rate of Parkinson's disease (PD).

Material And Methods: A wide range of non-motor symptoms (emotional-affective, cognitive, psychotic and behavioral disorders, fatigue, sleep disorders and autonomic disorders) was evaluated using validated scales and a number of serum neuromarkers responsible for neuroplasticity and neuronal survival processes (BDNF, PDGF, cathepsin D) in 71 patients with PD (mean age 65 (55; 70) years, disease duration 7 (4; 9) years, age of onset 57 (49; 62) years).

Results: The concentration of biomarkers (BDNF, PDGF and cathepsin D) was the lowest in the group of patients with a rapid PD progression rate (<0.001, =0.001 and =0.031, respectively), the severity of motor and most non-motor symptoms was higher (=0.023 and =0.001, respectively) compared to middle and slow progression rate. There were correlations between BDNF concentration and the severity of depression (=-0.63, <0.001), apathy (=-0.48, <0.001), impulsive behavioral disorders (=0.500, <0.001), level of cognitive functions (=0.54, <0.001), motor symptoms (=-0.43, <0.001); between PDGF level and the severity of motor manifestations of PD (=-0.30, =0.011), depression (=-0.70, <0.001), apathy (=-0.460, <0.001), the degree of severity of behavioral disorders (=0.742, <0.001). No significant correlations were observed between the level of cathepsin D and the severity of clinical manifestations of PD, which indicates the connection of cathepsin D with the general pathogenesis of PD.

Conclusion: The possibility of using serum proteins of the neurotrophin subfamily and the protein associated with autophagy, cathepsin D, as biomarkers that determine the prognosis of PD, is considered.